Chinese Shot Takes Controversial Path to Vaccinating the World
Bloomberg News, Bloomberg News Weidong Yin , Getty Images via Bloomberg
(Bloomberg) Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot thatâs been shrouded in controversy for months. Over in Beijing, though, the companyâs chief executive officer was unaware.
A study of some 128,000 Jakarta health workers released Wednesday found Sinovacâs vaccine known as CoronaVac was far more protective than clinical trials had indicated. A day earlier, it wasnât mentioned by CEO Yin Weidong in a wide-ranging interview with Bloomberg reporters, and representatives later confirmed the company didnât know the announcement was coming.
Share it
Editor’s note: This story is part of a series on the trends that will shape the industry in 2021. You can find all the articles on our trendline.
Three years ago, the Food and Drug Administration granted a landmark approval to the first gene therapy for an inherited disease, clearing a blindness treatment called Luxturna.
Since then, the regulator has approved one more gene therapy, the spinal muscular atrophy treatment Zolgensma, and given a green light for dozens of biotech and pharmaceutical companies to start clinical testing on others. Genetic medicines for a range of diseases, including hemophilia, sickle cell and several muscular dystrophies, appear in reach, and new science is galvanizing research.
Biotech Bulls See Bright Year Ahead 980waav.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 980waav.com Daily Mail and Mail on Sunday newspapers.